Previous 10 | Next 10 |
2023-07-21 08:14:47 ET BioNexus Gene Lab Corp ( BGLC ) +56% . Digital World Acquisition ( DWAC ) +23% jumps 29% amid settlement with SEC. Guardforce AI ( GFAI ) +16% . Bragg Gaming Group ( BRAG ) +13% . Emergent BioSolu...
2023-07-17 10:04:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BridgeBio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from a Phase 3 clinical trial . These results come from the company...
2023-07-17 08:28:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BYND Cannasoft Enterprise (NASDAQ: BCAN ) stock is dropping on Monday after the company announced an underwritten stock offering . BYND Cannasoft announced the underwrit...
2023-07-17 08:18:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change . According to a filing from Quoin Phar...
2023-07-17 08:16:34 ET Quoin Pharmaceuticals ( QNRX ) -91% . BYND Cannasoft Enterprises ( BCAN ) -47% . Apellis Pharmaceuticals ( APLS ) -33% . Baosheng Media Group Holdings Limited ( BAOS ) -13% . Ebix ( EBIX ) -11% after clarific...
Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders NEW YORK, June 13, 2023 - (NewMediaWire) - PCG Digital--Lipella Pharmaceuticals (Nasdaq: LIPO) is a clinical-stage biotechnology company addressing serious di...
ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treat...
2023-05-12 16:43:09 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman, Chief Executive Officer and Director Conference...
2023-05-08 17:04:33 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q1 GAAP EPS of -$0.34 misses by $0.06 . For further details see: Quoin Pharmaceuticals GAAP EPS of -$0.34 misses by $0.06
First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome ...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...